How Syndesi’s SV2A modulators may restore function to more synapses in AD
Syndesi Therapeutics S.A. is developing SV2A modulators to improve cognitive function in a range of indications including mild-to-moderate Alzheimer’s disease by regulating a broader sweep of neurotransmitters than available therapies.
Cognitive impairment in AD stems from progressive decline in synaptic function. In late-stage disease, a large portion of synapses are lost altogether. AChE inhibitors, which enhance levels of neurotransmitter acetylcholine (ACh) in the